Adjuvant and neoadjuvant chemotherapy for soft tissue sarcomas

Area of Science:

• Oncology
• Surgical Oncology
• Medical Oncology

Background:

• Soft tissue sarcomas are rare, heterogeneous mesenchymal tumors with a high risk of metastasis.
• Current treatments like surgery and radiotherapy achieve local control but often fail to prevent distant relapse.
• The role of adjuvant and neoadjuvant chemotherapy in improving survival outcomes remains debated due to inconsistent trial results.

Purpose of the Study:

• To review the current evidence on the efficacy of adjuvant and neoadjuvant chemotherapy for soft tissue sarcomas.
• To discuss the impact of chemotherapy on local relapse, metastatic disease, and overall survival.
• To provide recommendations for the management of high-risk sarcoma patients.

Main Methods:

• Review of meta-analyses and randomized controlled trials, including the SMAC meta-analysis and EORTC trials.
• Analysis of data on local and metastatic relapse, and overall survival.
• Discussion of the benefits and risks of adjuvant and neoadjuvant chemotherapy.

Main Results:

• Adjuvant chemotherapy demonstrated a significant impact on local and metastatic relapse in meta-analyses, with some showing survival benefits.
• Despite some positive findings, the latest EORTC adjuvant trial yielded negative results.
• Neoadjuvant chemotherapy may offer local benefits for surgical facilitation, but survival data are limited and subject to selection bias.

Conclusions:

• Adjuvant chemotherapy can be a reasonable option for carefully selected high-risk patients, provided they are fully informed about potential risks and benefits.
• Referral to a sarcoma multidisciplinary group is crucial for optimal management, including access to risk-stratified clinical trials.
• Further research is needed to clarify the role of chemotherapy and improve outcomes for soft tissue sarcoma patients.